Table 2 Univariate and multivariate analysis of post-failure prognostic factors in the distant failure group

Sex(Female vs. Male)

1.170(0.910–1.503)

0.220

NA

WHO Histology (I ~ II vs. III)

1.027 (0.648–1.629)

0.908

NA

Age, year (≤ 45vs.××45)

0.728(0.597–0.888)

0.002

NA

T stage ^a ( T3-4 vs. T1-2)

1.029(0.782–1.355)

0.837

NA

N stage ^a ( N2-3 vs. N0-1)

1.178(0.947–1.466)

0.141

NA

Overall stage ^a ( IVa vs. III)

1.089(0.886–1.338)

0.418

NA

EBV DNA load, copy/ml

(≥ 4000 vs. <4000)

1.209(0.965–1.514)

0.098

NA

IC cycle(2cycle vs. >2 cycle)

0.925(0.759–1.128)

0.440

NA

CCD, mg/m ²

0.505

NA

0

Reference

1-200

0.899(0.717–1.128)

0.359

> 200

0.748(0.411–1.361)

0.341

EDFFS

1.472(1.199–1.907)

< 0.001

1.375(1.118–1.691)

0.003

Post treatment

< 0.001

< 0.001

Supportive treatment

Reference

Surgery

0.128(0.084–0.197)

< 0.001

0.134(0.087–0.205)

< 0.001

Radiotherapy

0.291(0.191–0.444)

< 0.001

0.198(0.198–0.459)

< 0.001

Chemotherapy

0.255(0.201–0.325)

< 0.001

0.259(0.203–0.329)

< 0.001

Comprehensive therapy

0.090(0.049–0.165)

< 0.001

0.093(0.051–0.169)

< 0.001

unknown

0.176(0.072–0.433)

< 0.001

0.205(0.083–0.507)

0.001